NCCTG - N0872


Clinical Trial Title

NCCTG - N0872

Trial Status

Open to Enrollment

Start Date

April 2, 2013


Trial Type

Cancer (Oncology)

Specific Condition

Recurrent Glioblastoma


A Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma

  • You will be "randomized" into one of two study groups. The first group will receive the drug dasatinib in combination with bevacizumab. The second will receive a placebo (an inactive agent) in combination with bevacizumab. Randomization means that you are put into a group by chance (as in the flip of a coin).
  • Neither you nor your doctor can choose the group you will be in.

Eligibility Criteria

  • ≥18 years of age 
  • Histological confirmation of glioblastoma multiforme (grade 4 astrocytoma) as determined by pre-registration

  • Evidence of tumor progression by MRI or CT scan

  • ECOG Performance Status (PS) 0, 1, or 2.

  • Patient willing to discontinue use of aspirin or medications that inhibit platelet function 1 week prior to registration

  • Ability to complete questionnaire(s) by themselves or with assistance.

  • Provide informed written consent.

IRB Number

Legacy IRB


Sponsored by: NCCTG through Alliance for Clinical Trials in Oncology (‘Alliance’)

Principal Investigator Name

Regan Look, MD

Contact Name

Legacy Oncology Clinical Research



Contact Fax


Last Updated: Wednesday, September 18, 2013 01:30:03 PM